NCT04024631 Phenotyping Genetic Risk for Type 2 Diabetes
| NCT ID | NCT04024631 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pennsylvania |
| Condition | Diabetes Mellitus, Type 2 |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2019-06-17 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2019-06-17 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.
Eligibility Criteria
Inclusion Criteria: * Age 10-70 years * Prior participant of the UPenn Biobank or Center for Applied Genomics Biobank and agreed to be recontacted for future research. * Adults with BMI 25kg/m2 or higher, children and adolescents with BMI 85th percentile or higher Exclusion Criteria: * prior diagnosis of type 1, type 2, or secondary diabetes * use of medications that would impact glucose and insulin response such as steroids, metformin or other anti-diabetic medication * acute illness that may impact insulin and glucose dynamics * pregnancy * hypothalamic obesity or related genetic disorder of metabolism * recent systemic chemotherapy use * gastrointestinal impairment or surgery that may impact absorption * anemia * major organ system illness or any underlying condition requiring regular medication or treatment that could make implementation of the protocol or interpretation of the study results difficult * inability to comply with study protocol
Contact & Investigator
Jessica R Wilson, MD, MS
PRINCIPAL INVESTIGATOR
University of Pennsylvania
Frequently Asked Questions
Who can join the NCT04024631 clinical trial?
This trial is open to participants of all sexes, aged 10 Years or older, up to 70 Years, studying Diabetes Mellitus, Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04024631 currently recruiting?
Yes, NCT04024631 is actively recruiting participants. Contact the research team at jessica.wilson3@uphs.upenn.edu for enrollment information.
Where is the NCT04024631 trial being conducted?
This trial is being conducted at Philadelphia, United States, Philadelphia, United States.
Who is sponsoring the NCT04024631 clinical trial?
NCT04024631 is sponsored by University of Pennsylvania. The principal investigator is Jessica R Wilson, MD, MS at University of Pennsylvania. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.